Abstract
Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Current Pharmaceutical Biotechnology
Title: Antibody Aggregate Removal by Hydroxyapatite Chromatography
Volume: 10 Issue: 4
Author(s): Pete Gagnon and Kevin Beam
Affiliation:
Abstract: Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Export Options
About this article
Cite this article as:
Gagnon Pete and Beam Kevin, Antibody Aggregate Removal by Hydroxyapatite Chromatography, Current Pharmaceutical Biotechnology 2009; 10 (4) . https://dx.doi.org/10.2174/138920109788488833
DOI https://dx.doi.org/10.2174/138920109788488833 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Intra- and Interdomain Flexibility in Matrix Metalloproteinases: Functional Aspects and Drug Design
Current Pharmaceutical Design The ATP-Binding Cassette Transporter-2 (ABCA2) Increases Endogenous Amyloid Precursor Protein Expression and Abeta Fragment Generation
Current Alzheimer Research The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Denaturant Induced Equilibrium Unfolding and Conformational Transitional Studies of Germinated Fenugreek β-Amylase Revealed Molten Globule like State at Low pH
Protein & Peptide Letters Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents Neurochemicals Involved in Medullary Control of Common Carotid Blood Flow
Current Neuropharmacology Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Serotonergic and Behavioral Responses to Stress with Tryptophan in Rats
Current Psychopharmacology Word Forms of Modern Japanese Sound Symbolic Words Not Listed in Dictionaries
Neuroscience and Biomedical Engineering (Discontinued) Hangover Research Needs: Proceedings of the 5th Alcohol Hangover Research Group Meeting
Current Drug Abuse Reviews Pharmacotherapy in Pedatric PTSD: A Developmentally-Focused Review of the Evidence
Current Psychopharmacology Neutralization of Interleukin-1β Reduces Vasospasm and Alters Cerebral Blood Vessel Density Following Experimental Subarachnoid Hemorrhage in Rats
Current Neurovascular Research Sedation in PACU: The Role of Propofol
Current Drug Targets Development and Optimization of Press Coated Floating Pulsatile Drug Delivery of Sumatriptan Succinate
Current Drug Delivery Melanin-Concentrating Hormone as a Metabolic and Cognitive Regulatory Factor
Current Medicinal Chemistry - Central Nervous System Agents Fine Tuning of Intracellular Ca<sup>2+</sup> Content by Pharmacological Agents – A Strategy to Prevent Synapse Loss in Alzheimer Disease Hippocampal Neurons
Current Alzheimer Research